Anti-CD47 antibodies or engineered SIRPα–Fc fusion were shown to restore macrophage ability to phagocytose cancer cells and prime cytotoxic CD8 T-cells, leading to the tumor regression in several tumor models and in clinical trials. This evidence concerns the gene SIRPA and neoplasm.